Latest Period
Q2 2026
Security Snapshot
VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) Institutional Ownership
CUSIP: 92532F100
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
1,740
Shares (Excl. Options)
240,874,010
Price
$496.73
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- VRTX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 240,874,010
- Total 13F value
- $119,457,016,300
- Portfolio coverage rank
- 0.04%
- Share change
- +7,068,949
- Value change
- +$3,571,506,104
- Number of holders
- 1,740
- Shares outstanding
- 254,406,089
- SEC-reported price per share
- $479.00
- Insider filing price
- $479.00
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock is tracked under CUSIP 92532F100.
- 1740 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 1,693 to 1,740 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $104,937,762,860 to $119,457,016,300.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 1740 institutions filings for Q2 2026.
Security key
92532F100
Latest holder period
Q2 2026
13F holders
1,740
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
VRTX full holder history
VERTEX PHARMACEUTICALS INC / MA SEC filings
VERTEX PHARMACEUTICALS INC / MA company facts
VERTEX PHARMACEUTICALS INC / MA insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92532F100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
VRTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Capital World Investors | 10% | -10% | $11,096,649,178 | -$1,314,996,426 | 25,695,015 | -11% | Capital World Investors | 31 Mar 2026 |
| Capital Research Global Investors | 8.3% | +21% | $9,129,161,524 | +$1,649,759,182 | 21,139,169 | +22% | Capital Research Global Investors | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.5% | $8,500,369,377 | 19,036,076 | Vanguard Capital Management | 31 Mar 2026 | |||
| FMR LLC | 3.6% | $4,642,686,284 | 9,220,827 | FMR LLC | 31 Dec 2024 |
As of 30 Jun 2026, 1,740 institutional investors reported holding 240,874,010 shares of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX). This represents 95% of the company’s total 254,406,089 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
67%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Capital World Investors | 10% | 26,115,014 | +2.9% | 1.5% | $12,972,221,775 |
| BlackRock, Inc. | 9.5% | 24,109,373 | +0.58% | 0.18% | $11,975,848,722 |
| Capital Research Global Investors | 7.7% | 19,490,637 | -7.7% | 1.4% | $9,681,703,171 |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.5% | 16,580,713 | +0.41% | 0.18% | $8,236,137,569 |
| STATE STREET CORP | 4.7% | 11,871,459 | +1.2% | 0.17% | $5,896,909,829 |
| Invesco Ltd. | 3.2% | 8,043,052 | +51% | 0.32% | $3,995,225,251 |
| JPMORGAN CHASE & CO | 2.6% | 6,517,600 | -7.3% | 0.19% | $3,256,519,923 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 6,017,848 | -2% | 0.16% | $2,975,811,180 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.9% | 4,878,987 | -5.2% | 0.11% | $2,423,539,213 |
| Capital International Investors | 1.8% | 4,695,144 | -8.4% | 0.48% | $2,332,267,678 |
| LOOMIS SAYLES & CO L P | 1.5% | 3,920,953 | -2.1% | 2.5% | $1,947,654,924 |
| FRANKLIN RESOURCES INC | 1.3% | 3,347,253 | +507% | 0.36% | $1,662,681,008 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.3% | 3,247,658 | +1.1% | 0.28% | $1,613,209,159 |
| MORGAN STANLEY | 1.3% | 3,242,139 | +1.7% | 0.09% | $1,610,469,452 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.2% | 3,086,683 | +0.96% | 0.28% | $1,533,248,046 |
| BANK OF AMERICA CORP /DE/ | 1.2% | 3,039,178 | +5.6% | 0.1% | $1,509,650,819 |
| ALLIANCEBERNSTEIN L.P. | 1.2% | 3,019,315 | -23% | 0.49% | $1,348,244,920 |
| JENNISON ASSOCIATES LLC | 1.2% | 2,998,530 | +9.4% | 0.89% | $1,489,459,615 |
| NORGES BANK | 1.2% | 2,971,681 | 0.15% | $1,476,123,103 | |
| AMERIPRISE FINANCIAL INC | 1% | 2,604,822 | -1.1% | 0.26% | $1,293,902,477 |
| NORTHERN TRUST CORP | 0.98% | 2,486,478 | -3% | 0.14% | $1,235,108,216 |
| GOLDMAN SACHS GROUP INC | 0.98% | 2,481,761 | +2.6% | 0.13% | $1,232,765,009 |
| Clearbridge Investments, LLC | 0.92% | 2,342,915 | -13% | 0.96% | $1,163,795,944 |
| VICTORY CAPITAL MANAGEMENT INC | 0.85% | 2,173,152 | +15% | 0.61% | $1,079,501,899 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.8% | 2,041,282 | +6.3% | 0.13% | $1,013,966,008 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
50
Latest
Q2 2026
Rows shown
1-25 of 50
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 240,874,010 | $119,457,016,300 | +$3,571,506,104 | $496.73 | 1,740 |
| 2026 Q1 | 235,103,224 | $104,937,762,860 | -$1,995,984,610 | $446.54 | 1,693 |
| 2025 Q4 | 235,816,482 | $106,864,033,167 | +$1,342,369,699 | $453.36 | 1,664 |
| 2025 Q3 | 231,845,620 | $90,712,440,433 | -$3,681,628,852 | $391.64 | 1,507 |
| 2025 Q2 | 240,735,835 | $107,165,642,790 | +$1,856,744,900 | $445.20 | 1,543 |
| 2025 Q1 | 236,653,399 | $114,743,267,144 | +$569,969,794 | $484.82 | 1,597 |
| 2024 Q4 | 236,056,630 | $95,094,515,159 | +$124,454,808 | $402.70 | 1,542 |
| 2024 Q3 | 234,301,041 | $108,951,765,309 | -$108,863,209 | $465.08 | 1,532 |
| 2024 Q2 | 234,132,938 | $109,741,428,164 | +$127,466,437 | $468.72 | 1,538 |
| 2024 Q1 | 233,778,905 | $97,614,728,920 | -$351,588,308 | $418.01 | 1,481 |
| 2023 Q4 | 234,732,281 | $95,518,842,840 | -$282,404,031 | $406.89 | 1,430 |
| 2023 Q3 | 235,201,359 | $81,839,440,920 | -$491,731,898 | $347.74 | 1,268 |
| 2023 Q2 | 236,903,503 | $83,231,226,220 | -$329,673,784 | $351.91 | 1,270 |
| 2023 Q1 | 237,449,022 | $74,800,726,409 | +$551,796,768 | $315.07 | 1,191 |
| 2022 Q4 | 237,264,020 | $68,520,934,164 | +$69,172,686 | $288.78 | 1,206 |
| 2022 Q3 | 237,170,581 | $68,704,605,708 | +$746,235,756 | $289.54 | 1,108 |
| 2022 Q2 | 234,049,687 | $65,932,675,845 | +$619,489,758 | $281.79 | 1,093 |
| 2022 Q1 | 233,557,250 | $60,872,369,529 | +$1,115,223,036 | $260.97 | 1,050 |
| 2021 Q4 | 229,577,277 | $50,395,687,889 | -$237,458,680 | $219.60 | 1,015 |
| 2021 Q3 | 230,800,835 | $41,840,598,359 | -$222,800,189 | $181.39 | 920 |
| 2021 Q2 | 232,062,084 | $46,728,254,072 | -$411,655,570 | $201.63 | 961 |
| 2021 Q1 | 235,696,332 | $50,611,371,510 | -$676,555,551 | $214.89 | 983 |
| 2020 Q4 | 238,859,796 | $56,374,238,590 | -$907,518,096 | $236.34 | 952 |
| 2020 Q3 | 242,062,493 | $65,824,669,920 | -$146,259,561 | $272.12 | 931 |
| 2020 Q2 | 242,428,011 | $70,341,346,452 | -$453,115,099 | $290.31 | 949 |